ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Lonza, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a mixture of 1-bromo-3chloro-5,5-dimethylhydantoin; 1,3dichloro-5,5-dimethylhydantoin; and 1,3-dichloro-5-ethyl-5-methylhydantoin as a slimicide in the manufacture of paper and paperboard intended to contact food.

DATES: Written comments on the petitioner's environmental assessment by July 14, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Mitchell A. Cheeseman, Center for Food Safety and Applied Nutrition (HFS-217), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3083.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 3B4382) has been filed by Lonza, Inc., c/o Delta Analytical Corp., 7910 Woodmont Ave., Bethesda, MD 20814. The petition proposes to amend the food additive regulations in § 176.300 Slimicides (21 CFR 176.300) to provide for the safe use of a mixture of 1-bromo-3-chloro-5,5dimethylhydantoin; 1,3-dichloro-5,5dimethylhydantoin; and 1,3-dichloro-5ethyl-5-methylhydantoin as a slimicide in the manufacture of paper and paperboard intended to contact food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4 (b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before July 14, 1995, submit to the Docket Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m.,

Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: May 24, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95-14463 Filed 6-13-95; 8:45 am] BILLING CODE 4160-01-F

National Institutes of Health

Division of Research Grants; Notice of **Closed Meetings**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications

Name of SEP: Clinical Sciences.

Date: June 25, 1995.

Time: 1:00 p.m. Place: NIH, Rockledge II, Room 4140

Telephone Conference.

Contact Person: Dr. Larry Pinkus, Scientific Review Administrator, 6701 Rockledge Drive, Room 4140, Bethesda, MD 20892, (301) 435-

Name of SEP: Clinical Sciences.

Date: June 26, 1995.

Time: 1:30 p.m.

Place: NIH, Rockledge II, Room 4140

Telephone Conference.

Contact Person: Dr. Larry Pinkus, Scientific Review Administrator, 6701 Rockledge Drive, Room 4140, Bethesda, MD 20892, (301) 435-

Purpose/Agenda: To review Small Business Innovation Research Program grant applications.

Name of SEP: Multidisciplinary Sciences. Date: July 10-11, 1995.

Time: 1:00 p.m.

Place: Crowne Plaza, Rockville, MD. Contact Person: Dr. Harish Chopra, Scientific Review Admin., 6701 Rockledge Drive, Room 5112, Bethesda, MD 20892,

(301) 435-51160.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as

patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 7, 1995.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 95-14535 Filed 6-13-95; 8:45 am] BILLING CODE 4140-01-M

National Institutes of Health; National Cancer Institute: Notice of Closed Meetings

Pursuant to Sec. 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

Purpose/Agenda: Review, discussion and evaluation of individual grant applications.

Committee Name: Subcommittee B of the Cancer Research Manpower and Education Review Committee.

Contact Person: Dr. Neil B. West, Room 611D, Executive Plaza North, 6130 Executive Blvd., Bethesda, MD 20892, Telephone: (301) 402-2785

Date of Meeting: June 20-21, 1995. Place of Meeting: The Georgetown Inn, 1310 Wisconsin Avenue, NW., Washington, DC 20007.

Time: 8 a.m.

Committee Name: Subcommittee D of the Cancer Centers and Research Programs Review Committee.

Contact Person: Dr. John Abrell, Room 635B, Executive Plaza North, 6130 Executive Blvd., Bethesda, MD 20892, Telephone: (301)

Date of Meeting: July 31-August 1, 1995. Place of Meeting: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Time: 8 a.m.

Committee Name: Subcommittee A of the Cancer Centers and Research Programs Review Committee.

Contact Person: Dr. David E. Maslow, Room 643A, Executive Plaza North, 6130 Executive Blvd., Bethesda, MD 20892, Telephone: (301) 496-2330.

Date of Meeting: August 3-4, 1995. Place of Meeting: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

Time: 8 a.m.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable